AcelRx Pharmaceuticals, Inc. (ACRX) Receives Buy Rating from Jefferies Group LLC
Jefferies Group LLC restated their buy rating on shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) in a research note released on Friday, Marketbeat.com reports. The firm currently has a $7.00 price objective on the specialty pharmaceutical company’s stock.
Separately, Zacks Investment Research lowered AcelRx Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, July 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $8.67.
AcelRx Pharmaceuticals (NASDAQ ACRX) traded up 31.25% on Friday, reaching $3.15. The company’s stock had a trading volume of 11,026,343 shares. The firm has a 50-day moving average of $2.42 and a 200 day moving average of $2.75. AcelRx Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $4.08. The company’s market capitalization is $142.95 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.06. The business had revenue of $3.11 million during the quarter, compared to analysts’ expectations of $2.36 million. AcelRx Pharmaceuticals had a negative net margin of 273.65% and a negative return on equity of 478.66%. On average, equities research analysts anticipate that AcelRx Pharmaceuticals will post ($1.10) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/acelrx-pharmaceuticals-inc-acrx-receives-buy-rating-from-jefferies-group-llc/1447033.html.
In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $2.40, for a total value of $2,100,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 28.10% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 6,942 shares in the last quarter. ING Groep NV raised its stake in shares of AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 26,000 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares in the last quarter. 30.27% of the stock is currently owned by hedge funds and other institutional investors.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.